ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Back to Protocols
Beginner
8 weeks

Brain Stack Protocol

Enhanced focus, memory, cognitive performance, and reduced anxiety

Peptide Stack

Preparation

Both Semax and Selank are administered intranasally - no injections required. Store at 2-8°C. Use nasal spray bottles for convenient administration.

Administration

Administer Semax intranasally in the morning for focus and cognitive enhancement. Selank can be used once (morning) or twice daily (morning and afternoon) for anxiety reduction and calm focus. No food timing restrictions.

Monitoring

Track focus, memory, mood, anxiety levels, and cognitive performance daily. Many users report noticeable effects within 30-60 minutes of first dose. Benefits accumulate with consistent use.

Expected Timeline

Week 1: Immediate improvements in focus and reduced anxiety. Week 2-4: Enhanced memory consolidation and learning. Week 5-8: Sustained cognitive enhancement and stress resilience. Effects may persist 1-2 weeks after stopping.

Research Basis

Semax boosts BDNF (brain-derived neurotrophic factor) for neuroplasticity and cognitive enhancement. Selank modulates GABA for anxiolytic effects without sedation. Both are extensively researched in Russia with excellent safety profiles.

Safety Considerations

  • Generally very well tolerated
  • Avoid during pregnancy or breastfeeding
  • May cause mild nasal irritation
  • Start with lower doses to assess tolerance
  • Consult with a healthcare professional before starting
  • This protocol is for research and educational purposes only

Protocol Overview

A nootropic protocol using Semax and Selank for enhanced focus, memory, and reduced anxiety. Both are intranasal — no injections required. Semax boosts BDNF for neuroplasticity while Selank calms via GABA modulation.

Duration: 8 weeks Peptides: 2 Experience Level: Beginner

Peptide Stack

SEMAX

  • Dose: 300-600 mcg
  • Frequency: once daily
  • Timing: morning

View SEMAX Profile

SELANK

  • Dose: 250-500 mcg
  • Frequency: once or twice daily
  • Timing: morning and/or afternoon

View SELANK Profile

Preparation

Both Semax and Selank are administered intranasally - no injections required. Store at 2-8°C. Use nasal spray bottles for convenient administration.

Administration

Administer Semax intranasally in the morning for focus and cognitive enhancement. Selank can be used once (morning) or twice daily (morning and afternoon) for anxiety reduction and calm focus. No food timing restrictions.

Monitoring

Track focus, memory, mood, anxiety levels, and cognitive performance daily. Many users report noticeable effects within 30-60 minutes of first dose. Benefits accumulate with consistent use.

Expected Timeline

Week 1: Immediate improvements in focus and reduced anxiety. Week 2-4: Enhanced memory consolidation and learning. Week 5-8: Sustained cognitive enhancement and stress resilience. Effects may persist 1-2 weeks after stopping.

Research Basis

Semax boosts BDNF (brain-derived neurotrophic factor) for neuroplasticity and cognitive enhancement. Selank modulates GABA for anxiolytic effects without sedation. Both are extensively researched in Russia with excellent safety profiles.

Safety Considerations

  • Generally very well tolerated
  • Avoid during pregnancy or breastfeeding
  • May cause mild nasal irritation
  • Start with lower doses to assess tolerance
  • Consult with a healthcare professional before starting
  • This protocol is for research and educational purposes only

Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.

Important Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.